What is it about?
At present, there are many clinical trials of quzartinib in the treatment of acute myeloid leukemia. We summarize the existing clinical trials, indicating that quizartinib is an effective drug for the treatment of acute myeloid leukemia.
Featured Image
Photo by Arvin Chingcuangco on Unsplash
Why is it important?
By summarizing the existing clinical trials of quizartinib, including its effectiveness and side effects, the future direction of quizartinib for the treatment of acute myeloid leukemia was pointed out.
Perspectives
It is a great pleasure to write this article. Every medical progress has brought hope to patients. New targeted inhibitors for acute myeloid leukemia have shown their safety and effectiveness in multiple clinical trials, which gives us the motivation to continue and also allows us to find the direction from the current problems.
Fang Zhou
Southeast University
Read the Original
This page is a summary of: Quizartinib (AC220): a promising option for acute myeloid leukemia, Drug Design Development and Therapy, April 2019, Dove Medical Press,
DOI: 10.2147/dddt.s198950.
You can read the full text:
Contributors
The following have contributed to this page
